New long-acting insulin analogs: From clamp studies to clinical practice

Diabetes Care

Volumn 38, Issue 4, 2015, Pages 541-543

  Bolli, Geremia B ^a   Devries, J Hans ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN PEGLISPRO; ANTIDIABETIC AGENT; LONG ACTING INSULIN;

CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG COST; DRUG DOSE COMPARISON; DRUG MARKETING; DRUG SAFETY; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; RISK REDUCTION; DIABETES MELLITUS, TYPE 1; FEMALE; MALE;

DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE;

EID: 84942808281     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-2314     Document Type: Note

References (26)

1. Bolli GB, Owens DR. Insulin glargine. Lancet 2000;356:443-445.
2. Chapman TM, Perry CM. Insulin detemir: A review of its use in the management of type1 and 2 diabetes mellitus. Drugs 2004;64:2577- 2595.
3. Gough SC, Harris S, Woo V, Davies M. Insulin degludec: overview of a novel ultra long-acting basal insulin. Diabetes Obes Metab 2013;15: 301-309.
4. Becker RHA, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 unitscmL21 provides amore even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 unitscmL21. Diabetes Care 2015;38:637-643.
5. Swinnen SG, Holleman F, DeVries JH. The interpretation of glucose clamp studies of longacting insulin analogues: from physiology to marketing and back. Diabetologia 2008;51: 1790-1795.
6. Jørgensen KH, Hansen AK, Buschard K. Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs. Diabetes Res Clin Pract 2000;50:161-167.
7. Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012;14: 944-950.
8. Sinha VP, Howey DC, Choi SL, Mace KF, Heise T. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014;16:344-350.
9. Riddle MC, Bolli GB, Ziemen M, Muehlen- Bartmer I, Bizet F, Home PD; EDITION 1 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care 2014;37:2755-2762.
10. Yki-Jarvinen H, Bergenstal R, ZiemenM, et al.; EDITION 2 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes usingoral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 2014;37:3235-3243.
11. Terauchi Y, Koyama M, Cheng X, Shimizu S, Hirose T et al.; EDITION JP 2 study group. Glycaemic control and hypoglycaemia in Japanese people with T2DM receiving new insulin glargine 300 U/ml in combination with OADSs (EDITION JP 2). Diabetologia 2014;57(Suppl. 1):S401.
12. Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U/mL: glycemic control and hypoglycaemia in insulin-näive people with type 2 diabetes mellitus (EDITION 3). Diabetologia 2014;57(Suppl. 1):S387.
13. Home PD, Bergenstal RM, Riddle MC, et al. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/mL in people with type 1 diabetes (EDITION 4). Diabetologia 2014;57 (Suppl. 1):S69.
14. MatsuhisaM, KoyamaM, Cheng X, Shimizu S, Hirose T; EDITION JP 1 Study Group. New insulin glargine 300 U/mL: glycaemic control and hypoglycaemia in Japanese peoplewith T1DM(EDITION JP 1). Diabetologia 2014;57(Suppl. 1):S400.
15. Bergenstal RM, Bailey TS, Rodbard D, et al. Insulin glargine 300 U/mL vs 100 U/mL: glucose profiles of morning vs evening injections in adults with T1DM measured with continuous glucose monitoring (CGM). Diabetologia 2014; 57(Suppl. 1):S388.
16. Ritzel R, Roussel R, Bolli GB, Vinet L, Yki-Jarvinen H. New insulin glargine 300 U/ml: glycaemic control and hypoglycaemia in a metaanalysis of phase 3a EDITION clinical trials in people with type 2 diabetes mellitus. Diabetologia 2014;57(Suppl. 1):S394.
17. Heise T, Hermanski L, Nosek L. Feldman RS, Haahr H. Insulin degludec: four times lower pharmacodynamics variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012;14:859-864.
18. Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: A pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013;15: 175-184.
19. Henry RR, Mudaliar S, Ciaraldi TP, et al. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects. Diabetes Care 2014;37:2609-2615.
20. Porcellati F, Lucidi P, Cioli P, et al. Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. Diabetes Care 2015;38:503-512.
21. Steinstraesser A, Schmidt R, Bergmann K, Dahmen R, Becker RH. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab 2014;16:873-876.
22. Lucidi P, Porcellati F, Candeloro P, et al. Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: A dose-response study. Nutr Metab Cardiovasc Dis 2014;24:709-716.
23. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-328.
24. Becker RH, Novotny I, Teichert L, Bergmann K, Kapiza C. Low within- and between-day variability in exposure to new insulin glargine 300 U/mL. Diabetes Obes Metab. 26 November 2014 [Epub ahead of print]. DOI:10.1111/dom.12416.
25. Jeandidier N, Riddle MC, Bolli GB, et al. New insulin glargine 300 U/ml: efficacy and safety of flexible vs fixed dosing intervals in people with T2DM. Diabetologia 2014;57(Suppl. 1):S393.
26. Mathieu C, Hollander P, Miranda-Palma B, et al.; NN1250-3770 (BEGIN: Flex T1) Trial Investigators. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): A 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013;98:1154-1162.